Skp2在鼻型NK/T细胞淋巴瘤中的表达及临床意义

 目的 探讨Skp2与鼻型NK/T细胞淋巴瘤的预后及其他临床特点之间的关系。方法 收集95例鼻型NK/T细胞淋巴瘤患者临床病理学资料,用免疫组化方法检测肿瘤石蜡包埋标本的EB病毒编码RNA (EBV encoded RNA,EBER)、Skp2及Ki-67的表达情况,将Skp2阳性细胞比率超过50%的病例计入高表达组,低于50%的计入低表达组,分析患者的预后、EBER表达状态与Skp2、Ki 67表达率之间的关系。结果 在Skp2高表达组,中位生存期为20.54个月(95%CI:18.49-22.59),1年总体生存率为76%;在Skp2低表达组,中位生存期为17.54个月(95%CI:20.31 22.24),1年总体生存率为71%;在Skp2阴性组,中位生存期为个21.71个月(95%CI:11.15-16.18),1年总体生存率为91%。生存分析显示,Skp2高表达组与Skp2阴性组间差异具有统计学意义(P=0.035)。结论 Skp2的高表达可能是鼻腔NK/T细胞淋巴瘤预后的不良因素。

The expression and clinical significance of Skp2 in nasal type NK/T-cell lymphoma

Objective To discuss the correlation between Skp2 and the prognosis and other clinicopathological features of nasal type NK/T-cell lymphoma.Methods We collected the clinicopathological data of 95 cases of nasal type NK/T-cell lymphoma,detected the expression of EBV encoded RNA (EBER),Skp2 and Ki-67 of paraffin-embedded tissue of tumors using immunohistochemical method.The cases with the Skp2-positive rate of tumor cells above 50% were classified into high expression group,those with below 50% were classified into low expression group.We analyzed the correlation between the expression of Skp2 and Ki-67,and the prognosis or EBER status.Results In the high expression group,the mean overall survival was 20.54 months (95%CI:18.49-22.59),the 1-year overall survival rate was 76%.In the low expression group,the mean overall survival was 17.54 months (95%CI:20.31-22.24),the 1-year overall survival rate was 71%. In the negative expression group,the mean overall survival was 21.71 months (95%CI:11.15-16.18),the 1-year overall survival rate was 91%.There was statistical difference between Skp2 high expression group and Skp2 negative expression group (P<0.01).Conclusions The high expression of Skp2 maybe an independent unfavorable prognosis factor of nasal type NK/T-cell lymphoma.